Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Next Previous
X
Search
Trial Profile

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafenoquine (Primary) ; Chloroquine; Primaquine
  • Indications Falciparum malaria; Vivax malaria
  • Focus Therapeutic Use
  • Acronyms TRuST

    • Most Recent Events

    • 09 Jun 2023 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2023 According to a Medicines for Malaria Venture (MMV) and PATH media release, patients enrollment finished in August 2022, and in December 2022 a comprehensive dossier was submitted to CONITEC requesting the incorporation of single-dose tafenoquine and the STANDARD G6PD Test into the national health system (SUS).
    • 01 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top